Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality

References

• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med.354(1), 11–22 (2006).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med.354(1), 23–33 (2006).
   PubMed Web of Science ®Google Scholar
• Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol. Rec.81(1), 2–11 (2006).
   Google Scholar
• Meeting of the Immunization Strategic Advisory Group of Experts, April 2009 – conclusions and recommendations. Wkly Epidemiol. Rec.84(23), 220–236 (2009).
   PubMedGoogle Scholar
• Rotavirus vaccines: an update. Wkly Epidemiol. Rec.84(50), 533–540 (2009).
   PubMedGoogle Scholar
• Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 – conclusions and recommendations. Wkly Epidemiol. Rec.84(50), 517–532 (2009).
   PubMedGoogle Scholar
• Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. doi:10.1016/S1473-3099(11)70253-5 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis.12(2), 304–306 (2006).
   PubMed Web of Science ®Google Scholar
• Richardson V, Hernandez-Pichardo J, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N. Engl. J. Med.362(4), 299–305 (2010).
   PubMed Web of Science ®Google Scholar
• Richardson V, Parashar U, Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N. Engl. J. Med.365(8), 772–773 (2011).
   PubMed Web of Science ®Google Scholar
• do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med.8(4), e1001024 (2011).
   PubMed Web of Science ®Google Scholar
• Yen C, Armero Guardado JA, Alberto P et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr. Infect. Dis. J.30(Suppl. 1), S6–S10 (2011).
   PubMed Web of Science ®Google Scholar
• Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico. Pediatr. Infect. Dis. J.30(Suppl. 1), S11–S15 (2011).
   PubMed Web of Science ®Google Scholar
• Molto Y, Cortes JE, De Oliveira LH et al. Reduction of diarrhea-associated hospitalizations among children aged < 5 Years in Panama following the introduction of rotavirus vaccine. Pediatr. Infect. Dis. J.30(Suppl. 1), S16–S20 (2011).
   PubMed Web of Science ®Google Scholar
• Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr. Infect. Dis. J.30(7), e120–e125 (2011).
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr. Infect. Dis. J.29(4), 319–323 (2010).
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kundi M, Rendi-Wagner P et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine29(15), 2791–2796 (2011).
   PubMed Web of Science ®Google Scholar
• Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics126(3), e506–e512 (2010).
   PubMed Web of Science ®Google Scholar
• Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J. Infect. Dis.201(11), 1617–1624 (2010).
   PubMed Web of Science ®Google Scholar
• Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr. Infect. Dis. J.29(6), 489–494 (2010).
   PubMed Web of Science ®Google Scholar
• Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics127(1), e9–e15 (2011).
   PubMed Web of Science ®Google Scholar
• Rotavirus surveillance – worldwide, 2009. MMWR Morb. Mortal. Wkly Rep.60(16), 514–516 (2011).
   PubMedGoogle Scholar
• Steele AD, Reynders J, Scholtz F et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J. Infect. Dis.202(Suppl.), S93–S100 (2010).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med.362(4), 289–298 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet370(9601), 1757–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet376(9741), 606–614 (2010).
   PubMed Web of Science ®Google Scholar
• Zaman K, Dang DA, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet376(9741), 615–623 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur. J. Pediatr.169(11), 1379–1386 (2010).
   PubMed Web of Science ®Google Scholar
• Patel M, Pedreira C, De Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA301(21), 2243–2251 (2009).
   PubMed Web of Science ®Google Scholar
• Mast TC, Khawaja S, Espinoza F et al. Case–control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua. Pediatr. Infect. Dis. J.30(11), e209–e215 (2011).
   PubMed Web of Science ®Google Scholar
• Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• Hanlon P, Hanlon L, Marsh V et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet1(8546), 1342–1345 (1987).
   PubMed Web of Science ®Google Scholar
• De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet2(8498), 108 (1986).
   PubMed Web of Science ®Google Scholar
• Lanata CF, Black RE, del Aguila R et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J. Infect. Dis.159(3), 452–459 (1989).
   PubMed Web of Science ®Google Scholar
• Georges-Courbot MC, Monges J, Siopathis MR et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in central Africa. Res. Virol.142(5), 405–411 (1991).
   PubMedGoogle Scholar
• John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. BMJ1(6013), 812 (1976).
   PubMedGoogle Scholar
• John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol.96(4), 263–269 (1972).
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis.13(5), 926–939 (1991).
   PubMedGoogle Scholar
• Suharyono, Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year-old Indonesian children. Lancet340(8821), 689–694 (1992).
   PubMed Web of Science ®Google Scholar
• Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun.61(9), 3994–3997 (1993).
   PubMed Web of Science ®Google Scholar
• Linhares AC, Gabbay YB, Mascarenhas JD et al. Immunogenicity, safety and efficacy of tetravalent rhesus–human, reassortant rotavirus vaccine in Belem, Brazil. Bull. World Health Organ.74(5), 491–500 (1996).
   PubMed Web of Science ®Google Scholar
• Steele AD, De Vos B, Tumbo J et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine28(39), 6542–6548 (2008).
   PubMed Web of Science ®Google Scholar
• Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine13(3), 310–312 (1995).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis.187(6), 909–913 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine27(9), 1433–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J. Infect. Dis.200(Suppl. 1), S39–S48 (2009).
   PubMed Web of Science ®Google Scholar
• Moon SS, Wang Y, Shane AL et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr. Infect. Dis. J.29(10), 919–923 (2010).
   PubMed Web of Science ®Google Scholar
• Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J. Infect. Dis.174(Suppl. 1), S107–S111 (1996).
   PubMed Web of Science ®Google Scholar
• Dennehy PH, Brady RC, Halperin SA et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr. Infect. Dis. J.24(6), 481–488 (2005).
   PubMed Web of Science ®Google Scholar
• Goveia MG, DiNubile MJ, Dallas MJ, Heaton PM, Kuter BJ. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr. Infect. Dis. J.27(7), 656–658 (2008).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Pediatr. Infect. Dis. J.29(10), 957–963 (2010).
   PubMed Web of Science ®Google Scholar
• Boom JA, Tate JE, Sahni LC et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr. Infect. Dis. J.29(12), 1133–1135 (2010).
   PubMed Web of Science ®Google Scholar
• Correia JB, Patel MM, Nakagomi O et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J. Infect. Dis.201(3), 363–369 (2010).
   PubMed Web of Science ®Google Scholar
• de Palma O, Cruz L, Ramos H et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case–control study. BMJ340, c2825 (2010).
   PubMed Web of Science ®Google Scholar
• Justino MC, Linhares AC, Lanzieri TM et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr. Infect. Dis. J.30(5), 396–401 (2011).
   PubMed Web of Science ®Google Scholar
• Snelling TL, Andrews RM, Kirkwood CD, Culvenor S, Carapetis JR. Case–control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin. Infect. Dis.52(2), 191–199 (2011).
   PubMed Web of Science ®Google Scholar
• Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med.344(8), 564–572 (2001).
   PubMed Web of Science ®Google Scholar
• Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Wkly Rep.48(43), 1007 (1999).
   PubMedGoogle Scholar
• Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics110(6), e67 (2002).
   PubMed Web of Science ®Google Scholar
• Patel MM, Lopez-Collada VR, Bulhoes MM et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N. Engl. J. Med.364(24), 2283–2292 (2011).
   PubMed Web of Science ®Google Scholar
• Buttery JP, Danchin MH, Lee KJ et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine29(16), 3061–3066 (2011).
   PubMed Web of Science ®Google Scholar
• Belongia EA, Irving SA, Shui IM et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr. Infect. Dis. J.29(1), 1–5 (2010).
   PubMed Web of Science ®Google Scholar
• Haber P, Patel M, Izurieta HS et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics121(6), 1206–1212 (2008).
   PubMed Web of Science ®Google Scholar
• Cortese M. Estimates of benefits and potential risks of rotavirus vaccination in the U.S. Presented at: Advisory Committee on Immunization Practices Meeting. Atlanta, GA, USA, 27–28 October 2010.
   Google Scholar
• Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol. Rec.86(5), 38–43 (2011).
   PubMedGoogle Scholar
• Bines JE, Liem NT, Justice F et al. Validation of clinical case definition of acute intussusception in infants in Viet Nam and Australia. Bull. World Health Organ.84(7), 569–575 (2006).
   PubMed Web of Science ®Google Scholar
• Staat MA, Payne DC, Donauer S et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics128(2), e267–e275 (2011).
   PubMed Web of Science ®Google Scholar
• Yen C, Figueroa JR, Uribe ES et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J. Infect. Dis.204(5), 783–786 (2011).
   PubMed Web of Science ®Google Scholar
• Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009. Wkly Epidemiol. Rec.84(32), 325–332 (2009).
   PubMedGoogle Scholar
• Patel MM, Clark AD, Glass RI et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine27(22), 2916–2922 (2009).
   PubMed Web of Science ®Google Scholar
• Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J. Infect. Dis.168(2), 282–287 (1993).
   PubMed Web of Science ®Google Scholar
• Das BK, Gentsch JR, Hoshino Y et al. Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology197(1), 99–107 (1993).
   PubMed Web of Science ®Google Scholar
• Glass RI, Bhan MK, Ray P et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J. Infect. Dis.192(Suppl. 1), S30–S35 (2005).
   PubMed Web of Science ®Google Scholar
• Vethanayagam RR, Ananda Babu M, Nagalaxmi KS et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain I321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988–1999. J. Infect. Dis.189(12), 2282–2289 (2004).
   PubMed Web of Science ®Google Scholar
• Rippinger CM, Patton JT, McDonald SM. Complete genome sequence analysis of candidate human rotavirus vaccine strains RV3 and 116E. Virology405(1), 201–213 (2010).
   PubMed Web of Science ®Google Scholar
• Bhandari N, Sharma P, Taneja S et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis.200(3), 421–429 (2009).
   PubMed Web of Science ®Google Scholar
• Barnes GL, Lund JS, Adams L et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J. Paediatr. Child Health33(4), 300–304 (1997).
   PubMed Web of Science ®Google Scholar
• Barnes GL, Lund JS, Mitchell SV et al. Early Phase 2 trial of human rotavirus vaccine candidate RV3. Vaccine20(23–24), 2950–2956 (2002).
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Simonsen L, Vesikari T et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J. Infect. Dis.192(Suppl. 1), S22–29 (2005).
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Makhene MK, Mrukowicz J et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine17(20–21), 2715–2725 (1999).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen AV, Majuri J et al. Safety, efficacy, and immunogenicity of two dose of bovine–human (UK) and rhesus–rhesus–human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis.194(3), 370–376 (2006).
   PubMed Web of Science ®Google Scholar
• Global Advisory Committee on Vaccine Safety, 1–2 December 2005. Wkly Epidemiol. Rec.81(2), 15–19 (2006).
   PubMedGoogle Scholar
• Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine26(52), 6754–6758 (2008).
   PubMed Web of Science ®Google Scholar